
Bhatt also discusses how these findings inform the choice between dupilumab and mepolizumab under GOLD 2026.

Director, Center for Lung Analytics and Imaging Research (CLAIR), Endowed Professor of Airways Disease at the University of Alabama at Birmingham School of Medicine

Bhatt also discusses how these findings inform the choice between dupilumab and mepolizumab under GOLD 2026.

Bhatt discussed the latest data from a post-hoc analysis of the BOREAS and NOTUS trials.